IP Library Granted Patent US 11,067,585
Granted Patent B2
US 11,067,585 · App. 15/817,868 · Granted Jul 20, 2021

Method for monitoring cancer and/or inflammatory reaction based on RelB phosphorylation

Inventors: Veronique Baud (Paris, FR); Katy Billot (Bourg la Reine, FR)
Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS); UNIVERSITE PARIS DESCARTES; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
G01N33/6872C07K16/18G01N33/57484G01N2333/4703G01N2440/14G01N2500/04G01N2500/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,067,585
App. No.
15/817,868
Granted
Jul 20, 2021
Kind
B2
Abstract

The present Inventors demonstrated that the RelB subunit of NFκB plays a crucial role in promoting cell migration. More precisely, they identified that this pro-migratory activity is mediated by the activation of the NFκB pathway through RelB phosphorylation at serine 472. In a first aspect, the present invention proposes to monitor the activation of the NFκB pathway by following the phosphorylation status of said serine. Also, the present invention discloses methods and kits for prognosing the evolution of a disease involving cell migration in a subject—treated or not—suffering thereof, based on the detection of said RelB-S472 phosphorylation.

Claims (6)

1. The monoclonal antibody produced by hybridoma RA3-AF3, deposited at the Collection Nationale de Cultures de Microorganismes (CNCM) at the Institut Pasteur, 25, Rue du Docteur Roux, 75724 Paris, FR, on Nov. 18, 2020, under the deposit number CNCM 1-5612.

2. A method, comprising:

a) providing a sample;

b) contacting the sample with the monoclonal antibody of claim 1 ; and

c) detecting binding between the monoclonal antibody and ReIB (SEQ ID NO: 1) phosphorylated on serine 472 or a ReIB-homologue having at least 80% identity to (SEQ ID NO: 1) and phosphorylated on a corresponding serine, in said sample.

3. The method of claim 2 , wherein binding between the monoclonal antibody and ReIB (SEQ ID NO: 1) phosphorylated on serine 472 is detected.

Assignments (2)
CHANGE OF NAME Recorded Mar 25, 2022
From: UNIVERSITÉ DE PARIS
To: UNIVERSITÉ PARIS CITÉ
Reel/Frame 059504/0225 →
MERGER Recorded Jul 22, 2021
From: UNIVERSITE DE PARIS DESCARTES
To: UNIVERSITE DE PARIS
Reel/Frame 056958/0603 →